Literature DB >> 14736517

18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer.

G Zornoza1, M J Garcia-Velloso, J Sola, F M Regueira, L Pina, C Beorlegui.   

Abstract

AIM: The presence of axillary involvement is the most important prognostic factor in breast cancer. This study analysis the value of 18F-FDG PET in the detection of the lymph node status.
METHODS: This study includes 200 breast cancer patients. The PET scans were obtained after the injection of 370 MBq of 18F-FDG; the breast areas, axillary, supraclavicular and internal mammary lymph node chains were evaluated. In a subgroup of 100 patients the PET-FDG scan was complemented with the study of the sentinel node (SN) in those cases which did not demonstrate pathological lymph node uptake. The standardized uptake value (SUV) was related to the tumour characteristics of size, histological type, axillary status and histological grading.
RESULTS: The sensitivity and specificity of PET-FDG in the detection of axillary involvement was 84.1 and 97.8%, respectively. Seventeen false negative cases were obtained, and were associated with low SUV in the mammary tumour. In 15 cases the PET-FDG scans revealed pathological uptake foci that suggested involvement of the internal mammary chain.
CONCLUSIONS: The PET-FDG avoids routine SN study in those cases presenting axillary uptake, but it must be complemented by sentinel node study in those cases without pathological uptake. The association of PET-FDG and SN improves the sensitivity in the detection of axillary involvement. Its sensitivity and specificity in the analysis of axillary status can be extended to the evaluation of the internal mammary chain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14736517     DOI: 10.1016/j.ejso.2003.10.010

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  15 in total

1.  Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.

Authors:  Laura Gilardi; Concetta De Cicco; Marco Colleoni; Anna Cardillo; Emilia Montagna; Silvia Dellapasqua; Viviana Galimberti; Vincenzo Bagnardi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-10       Impact factor: 9.236

2.  [Non-invasive imaging modalities for preoperative axillary lymph node staging in patients with breast cancer].

Authors:  K Wasser; A Schnitzer; J Brade; S O Schoenberg
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

3.  MR lymphangiography with intradermal gadofosveset and human serum albumin in mice and primates.

Authors:  Takahito Nakajima; Baris Turkbey; Kohei Sano; Kazuhide Sato; Marcelino Bernardo; Robert F Hoyt; Peter L Choyke; Hisataka Kobayashi
Journal:  J Magn Reson Imaging       Date:  2013-10-10       Impact factor: 4.813

4.  PET Probe-Guided Surgery in Patients with Breast Cancer: Proposal for a Methodological Approach.

Authors:  Paolo Orsaria; Agostino Chiaravalloti; Alessandro Fiorentini; Chiara Pistolese; Gianluca Vanni; Alessandra Vittoria Granai; Dimitrios Varvaras; Roberta Danieli; Orazio Schillaci; Giuseppe Petrella; Oreste Claudio Buonomo
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

5.  Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients.

Authors:  Barbara J Fueger; Wolfgang A Weber; Andrew Quon; Tyler L Crawford; M S Allen-Auerbach; B S Halpern; Osman Ratib; Michael E Phelps; Johannes Czernin
Journal:  Mol Imaging Biol       Date:  2005 Sep-Oct       Impact factor: 3.488

Review 6.  A systematic review of FDG-PET in breast cancer.

Authors:  S Escalona; J A Blasco; M M Reza; E Andradas; N Gómez
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

Review 7.  FDG-PET for axillary lymph node staging in primary breast cancer.

Authors:  Flavio Crippa; Alberto Gerali; Alessandra Alessi; Roberto Agresti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

8.  Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.

Authors:  Keun Seok Lee; Jungsil Ro; Eun Sook Lee; Han Sung Kang; Seok Won Kim; Byung-Ho Nam; Youngmee Kwon; Eun-A Kim; Kyung Hwan Shin
Journal:  Invest New Drugs       Date:  2009-02-20       Impact factor: 3.850

9.  PET Tracers for Clinical Imaging of Breast Cancer.

Authors:  Iván Peñuelas; Inés Domínguez-Prado; María J García-Velloso; Josep M Martí-Climent; Macarena Rodríguez-Fraile; Carlos Caicedo; María Sánchez-Martínez; José A Richter
Journal:  J Oncol       Date:  2012-08-29       Impact factor: 4.375

10.  The Effects of Preoperative (18)F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study.

Authors:  Young Jin Choi; Young Duck Shin; Yoon Hee Kang; Moon Soo Lee; Min Koo Lee; Byung Sun Cho; Yoon Jung Kang; Ju Seung Park
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.